Lumida
/ABSI
⌘K
Absci Corp

Absci Corp

ABSI
$8.21USD-0.36%-0.03 today

MARKET CAP

1.4B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $9

52W RANGE

$2
$12

AI Summary

Stalk
Sell NowMedium

ABSI is in a Stage 3 distribution with price below the 9-, 20-, and 50-day moving averages, reinforced by a Bearish Pivot Point and lower highs/lows continuation. Medium-term bias is bearish, with tradability on rallies into the EMA/SMA resistance zone, and short-term weakness confirms a Sell Now posture targeting rejections at this region.

  • ABS-201 Phase 2 trial for endometriosis launches after promising Phase 1 safety data
  • AI-driven platform aligns with projected $8.5B AI in drug-discovery market by 2030
  • Q2 revenue of $0.3M vs. net loss of $33.2M underscores heavy cash burn
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$4.8M$5.7M$5.7M$4.5M$2.8M
YoY %+20.2%-0.5%-20.7%-38.2%
P / Sales85.2x35.7x59.4x63.7x170.5x
EV / Sales44.9x33.4x53.9x62.2x172.9x
Gross Profit, Adj.$4.8M$5.7M$5.7M$4.5M$2.8M
YoY %+20.2%-0.5%-20.7%-38.2%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit44.9x33.4x53.9x62.2x172.9x
EBITDA, Adj.$-68.6M$-93.7M$-80.2M$-95.5M$-108.6M
YoY %-36.6%+14.4%-19.1%-13.7%
Margin %-1434.2%-1630.6%-1402.3%-2106.3%-3877.7%
EV / EBITDA-3.1x-2.0x-3.8x-3.0x-4.5x
EBIT$-75.2M$-106.8M$-115.5M$-108.9M$-120.3M
YoY %-41.9%-8.2%+5.7%-10.5%
Margin %-1573.4%-1857.5%-2020.2%-2401.6%-4297.0%
EV / EBIT-2.9x-1.8x-2.7x-2.6x-4.0x
Net Income$-103.2M$-104.9M$-110.6M$-103.1M$-115.2M
YoY %-1.6%-5.4%+6.7%-11.7%
Net Margin-2159.0%-1825.4%-1933.6%-2274.1%-4113.7%
EPS (GAAP)-$2.08-$1.15-$1.20-$0.94-$0.84
YoY %+44.7%-4.3%+21.7%+10.6%